Corcept Therapeutics: Despite FDA Setback, Relacorilant Still Holds Potential

Corcept Therapeutics, the biotech company known for its cortisol‑modulating drugs, continues to generate solid revenue from its marketed product Korlym, which brought in over $559 million in the first nine months of 2025 and posted positive net income in the third quarter. Despite a surprise regulatory setback, the U.S. Food and Drug Administration (FDA) issued a complete response letter (CRL) rejecting Corcept’s New Drug Application for relacorilant as a treatment for hypertension secondary to hypercortisolism (Cushing’s syndrome), citing an insufficient benefit‑risk profile based on the data submitted — even though the drug had shown improvements in key clinical measures in its Phase III GRACE trial. However, the story doesn’t end there. Corcept’s strong balance sheet, underpinned by Korlym’s ongoing sales, provides financial support to pursue additional clinical evidence and regulatory engagement to address the FDA’s concerns, potentially keeping relacorilant’s future alive in this indication. Moreover, the drug remains under active development for other serious diseases, most notably platinum‑resistant ovarian cancer, where an FDA New Drug Application has been accepted and is under review with a decision expected by July 11, 2026. Positive data from the pivotal ROSELLA trial in this oncology setting suggest relacorilant could improve outcomes when combined with chemotherapy, offering hope for a new treatment option in a difficult‑to‑treat cancer. #CorceptTherapeutics #Relacorilant #FDA #BiotechNews #SlimScan #GrowthStocks #CANSLIM